Angiogenesis inhibitors used to treat NSCLC include monoclonal antibodies, small molecule VEGF receptor-tyrosine kinase inhibitors (VEGFR-TKIs), and VEGF Trap (Figure 1) [7]. This evidence concerns the gene KDR and non-small cell lung carcinoma.